03 December 2002 - U.S. Patent and Trademark Office

TM 302 OFFICIAL GAZETTE DEC 3, 2002
CLASS 5—(Continued).
SN 76-057,017. ONDRE INTERNATIONAL, INC., MONTER-
EY, CA. FILED 5-23-2000.
BUDDY’S BLEND
NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO
USE "BLEND", APART FROM THE MARK AS SHOWN.
FOR BUG REPELLENT (U.S. CLS. 6, 18, 44, 46, 51 AND
52).
FIRST USE 1-0-2000; IN COMMERCE 1-0-2000.
SN 76-112,425. BAXTER AKTIENGESELLSCHAFT, A-1220
VIENNA, AUSTRIA, FILED 8-18-2000.
THE MARK CONSISTS OF A TULIP DESIGN SET INSIDE
A TRIANGLE WHICH IS SET INSIDE A CIRCLE.
FOR TISSUE ADHESIVES FOR USE IN HUMANS (U.S.
CLS. 6, 18, 44, 46, 51 AND 52).
SN 76-113,440. OMEGA NATURAL SCIENCE, INC., WAL-
THAM, MA. BY ASSIGNMENT CX RESEARCH, LLC,
AUSTIN, TX. FILED 8-21-2000.
OMEGA BRITE
NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO
USE "OMEGA", APART FROM THE MARK AS SHOWN.
FOR NUTRITIONAL SUPPLEMENTS CONTAINING
OMEGA 3 FATTY ACIDS (U.S. CLS. 6, 18, 44, 46, 51
AND 52).
FIRST USE 1-1-2000; IN COMMERCE 1-1-2000.
CLASS 5—(Continued).
SN 76-113,580. EPIGENESIS PHARMACEUTICALS, INC,
CRANBURY, NJ. FILED 8-16-2000.
RAINBOWABC
FOR AEROSOL DISPENSERS FOR MEDICAL USE,
SOLD FILLED OR IN A KIT WITH, AND FOR THE
DELIVERY OF PHARMACEUTICAL PREPARATIONS
FOR USE IN TESTING, AND PROPHYLACTIC AND
THERAPEUTIC TREATMENT, OF AILMENTS, DIS-
EASES AND CONDITIONS ASSOCIATED WITH RE-
SPIRATORY, AIRWAY AND PULMONARY DISEASES,
SUCH AS ASTHMA, PULMONARY VASOCONSTRIC-
TION, INFLAMMATION, ALLERGIES, ASTHMA, IM-
PEDED RESPIRATION, ACUTE RESPIRATORY
DISTRESS SYNDROME (ARDS), RENAL DAMAGE
AND FAILURE, FOR EXAMPLE WHEN ASSOCIATED
WITH ISCHEMIA, ADMINISTRATION OF CERTAIN
DRUGS, IN HEART AND CARDIOVASCULAR STRESS
TESTS, SIDE EFFECTS ASSOCIATED WITH ADENO-
SINE AND OTHER COMPOUNDS, SUCH AS WHEN
TREATING SUPRA VENTRICULAR TACHYCARDIA
(SVT), INFANTILE RESPIRATORY DISTRESS SYN-
DROME (INFANTILE RDS), PAIN, CYSTIC FIBROSIS,
ALLERGIC RHINITIS, ALLERGIC BRONCHITIS, PUL-
MONARY HYPERTENSION, PULMONARY VASOCON-
STRICTION, EMPHYSEMA, CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD), AS WELL AS CAN-
CERS SUCH AS LEUKEMIAS, LYMPHOMAS, CARCI-
NOMAS, AND THE LIKE, E.G. COLON CANCER,
BREAST CANCER, LUNG CANCER, PANCREATIC
CANCER, HEPATOCELLULAR CARCINOMAS, KIDNEY
CANCER, MELANOMA, HEPATIC METASTASES, ETC.,
AS WELL AS OTHER METASTATIC CANCERS, E.G.
CANCERS WHICH METASTASIZED TO THE LUNG(S),
BREAST AND PROSTATE, AIRWAY DISEASES AND
CONDITIONS INCLUDING THOSE THAT MAY BE
ASSOCIATED WITH HYPER-SENSITIVITY OR HYER-
RESPONSIVENESS TO ADENOSINE, BRONCHOCON-
STRICTION, DIFFICULT BREATHING, IMPEDED AND
OBSTRUCTED LUNG AIRWAYS, ALLERGY(IES) AND /
OR INFLAMMATION, WHICH IN MANY CASES ARE
ADENOSINE RECEPTOR ASSOCIATED SYMPTOMS,
AND MORE GENERALLY FOR TESTING AND TREAT-
MENT OF HUMAN AND NON-HUMAN ANIMAL AIL-
MENT INCLUDED (U.S. CLS. 6, 18, 44, 46, 51 AND 52).
FIRST USE 7-0-1998; IN COMMERCE 8-0-1998.
SN 76-114,562. NANOCARRIER CO., LTD., CHIBA 277-0882,
JAPAN, FILED 8-21-2000.
MEDICELLE
FOR DRUG DELIVERY SYSTEMS, NAMELY, POLY-
MER NANOPARTICLES FOR ENCAPSULATING AND
BINDING PHARMACEUTICAL PRODUCTS, AND
POLYMER NANOPARTICLES FOR ENCAPSULATING
AND BINDING MEDICAL DIAGNOSTIC REAGENTS;
PHARMACEUTICAL PRODUCTS, NAMELY, A PHAR-
MACEUTICAL PREPARATION CONTAINING NANO-
CAPSULES BOUND TO A BLOCK CO-POLYMER USED
TO TREAT A VARIETY OF ILLNESSES, DISEASES, AND
MEDICAL CONDITIONS; AND MEDICAL DIAGNOSTIC
REAGENTS ENCAPSULATED IN OR BOUND TO POLY-
MERNANOPARTICLES(U.S.CLS.6,18,44,46,51AND
52).